Abstract
Thirteen subjects with trigeminal neuralgia were treated with botulinum-A neurotoxin (BoNT/A) in an open-label pilot study. After BoNT/A, visual analog scale score, surface area of pain, and therapeutic coefficient were reduced in all patients and for all branch trigeminal nerves studied. Therefore, BoNT/A is an efficient treatment. There were no major side effects. A placebo-controlled clinical trial is needed to confirm these findings.
MeSH terms
-
Aged
-
Analgesics / therapeutic use
-
Anticonvulsants / therapeutic use
-
Blepharoptosis / chemically induced
-
Botulinum Toxins, Type A / administration & dosage*
-
Botulinum Toxins, Type A / adverse effects
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neuropeptides / antagonists & inhibitors
-
Neuropeptides / metabolism
-
Neurotoxins / administration & dosage
-
Neurotoxins / adverse effects
-
Nociceptors / drug effects
-
Nociceptors / physiology
-
Pain Measurement / drug effects
-
Pain Threshold / drug effects
-
Pain Threshold / physiology
-
Pilot Projects
-
Sensory Receptor Cells / drug effects
-
Sensory Receptor Cells / physiology
-
Synaptic Transmission / drug effects
-
Synaptic Transmission / physiology
-
Treatment Outcome
-
Trigeminal Nerve / drug effects*
-
Trigeminal Nerve / physiopathology
-
Trigeminal Neuralgia / drug therapy*
-
Trigeminal Neuralgia / physiopathology
Substances
-
Analgesics
-
Anticonvulsants
-
Neuropeptides
-
Neurotoxins
-
Botulinum Toxins, Type A